Stockholm, Sweden & Cambridge, Mass., May 26, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced participation in the Jefferies Global Healthcare Conference:
Location: New York, New York
Format: Fireside chat and 1×1 meetings
Webcast: Link
Presentation Date and Time: Thursday June 4th at 2:35 PM
Participants: Ahmed Mousa, CEO, and Bernt van den Blink, CMO
For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
Vicore Pharma is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com